Hepatocellular carcinoma stem cell-like cells are enriched following low-dose 5-fluorouracil chemotherapy

Oncology Letters

Volumn 12, Issue 4, 2016, Pages 2511-2516

  Zhan, Yongqiang ^a   Mou, Lisha ^a,b   Cheng, Kangwen ^c   Wang, Chengyou ^a   Deng, Xuesong ^a   Chen, Junren ^a   Fan, Zhibing ^a   Ni, Yong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

^b PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^c Tongling People's Hospital of Anhui Province   (China)

Author keywords

5 fluorouracil; Cancer stem cell like cells; Chemotherapy; Hepatocellular carcinoma; Tumor

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; FLUOROURACIL; PROTEIN BAX; PROTEIN BCL 2;

ARTICLE; CANCER STEM CELL; CELL CULTURE; CELL CYCLE ASSAY; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CELL MOTILITY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HEPATOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LOW DRUG DOSE; WESTERN BLOTTING; WOUND HEALING;

EID: 84983443348     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4975     Document Type: Article

References (27)

1. Segura-Lopez FK, Güitrón-Cantu A and Torres J: Association between spp. infections and hepatobiliary malignancies: A review. World J Gastroenterol 21: 1414-1423, 2015.
2. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, et al: Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44: 760-764, 2012.
3. Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer 14: 1-10, 2015.
4. Wang C, Guo Y, Wang J and Min Z: Annexin A2 knockdown inhibits hepatoma cell growth and sensitizes hepatoma cells to 5-fluorouracil by regulating β-catenin and cyclin D1 expression. Mol Med Rep 11: 2147-2152, 2015.
5. Focaccetti C, Bruno A, Magnani E, Bartolini D, Principi E, Dallaglio K, Bucci EO, Finzi G, Sessa F, Noonan DM and Albini A: Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS One 10: e0115686, 2015.
6. Sun HC and Tang ZY: Preventive treatments for recurrence after curative resection of hepatocellular carcinoma-a literature review of randomized control trials. World J Gastroenterol 9: 635-640, 2003.
7. Kumar D, Gupta D, Shankar S and Srivastava RK: Biomolecular characterization of exosomes released from cancer stem cells: Possible implications for biomarker and treatment of cancer. Oncotarget 6: 3280-3291, 2015.
8. Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, Quinn MA, Thompson EW, Findlay JK and Ahmed N: Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol Cancer 12: 24, 2013.
9. Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ and Guan XY: Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 6: 1146-1153, 2008.
10. Jing F, Kim HJ, Kim CH, Kim YJ, Lee JH and Kim HR: Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases. Int J Oncol 46: 1582-1588, 2015.
11. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, et al: Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 24: 837-852, 2010.
12. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H and Taniguchi H: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44: 240-251, 2006.
13. Song J, Chang I, Chen Z, Kang M and Wang CY: Characterization of side populations in HNSCC: Highly invasive, chemoresistant and abnormal Wnt signaling. PLoS One 5: e11456, 2010.
14. Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, Kumar J, Thompson EW, Quinn MA, Findlay JK and Ahmed N: Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem 112: 2850-2864, 2011.
15. Mannelli G, Magnelli L, Deganello A, Busoni M, Meccariello G, Parrinello G and Gallo O: Detection of putative stem cells markers, CD44/CD133, in primary and lymph node metastases in head and neck squamous cell carcinomas. A preliminary immunohistochemical and in vitro study. Clin Otolaryngol 40: 312-320, 2015.
16. Arnold KM, Opdenaker LM, Flynn D and Sims-Mourtada J: Wound healing and cancer stem cells: Inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastasis 8: 1-13, 2015.
17. Xu ZY, Tang JN, Xie HX, Du YA, Huang L, Yu PF and Cheng XD: 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells. Int J Biol Sci 11: 284-294, 2015.
18. Alama A, Gangemi R, Ferrini S, Barisione G, Orengo AM, Truini M, Bello MG and Grossi F: CD133-positive cells from non-small cell lung cancer show distinct sensitivity to cisplatin and afatinib. Arch Immunol Ther Exp (Warsz) 63: 207-214, 2015.
19. Wang M, Wang Y and Zhong J: Side population cells and drug resistance in breast cancer. Mol Med Rep 11: 4297-4302, 2015.
20. Leccia F, Del Vecchio L, Mariotti E, Di Noto R, Morel AP, Puisieux A, Salvatore F and Ansieau S: ABCG2, a novel antigen to sort luminal progenitors of BRCA1-breast cancer cells. Mol Cancer 13: 213, 2014.
21. Guzel E, Karatas OF, Duz MB, Solak M, Ittmann M and Ozen M: Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer. Prostate 74: 1498-1505, 2014.
22. Feuerhake F, Sigg W, Höfter EA, Dimpfl T and Welsch U: Immunohistochemical analysis of Bcl-2 and Bax expression in relation to cell turnover and epithelial differentiation markers in the non-lactating human mammary gland epithelium. Cell Tissue Res 299: 47-58, 2000.
23. Lv XG, Ji MY, Dong WG, Lei XF, Liu M, Guo XF, Wang J and Fang C: EBP50 gene transfection promotes 5-fluorouracil-induced apoptosis in gastric cancer cells through Bax-and Bcl-2-triggered mitochondrial pathways. Mol Med Rep 5: 1220-1226, 2012.
24. Quan M, Wang P, Cui J, Gao Y and Xie K: The roles of FOXM1 in pancreatic stem cells and carcinogenesis. Mol Cancer 12: 159, 2013.
25. Bergamaschi A, Madak-Erdogan Z, Kim YJ, Choi YL, Lu H and Katzenellenbogen BS: The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells. Breast Cancer Res 16: 436, 2014.
26. Teh MT, Gemenetzidis E, Patel D, Tariq R, Nadir A, Bahta AW, Waseem A and Hutchison IL: FOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma. PLoS One 7: e34329, 2012.
27. Yamashita T, Kitao A, Matsui O, Hayashi T, Nio K, Kondo M, Ohno N, Miyati T, Okada H, Yamashita T, et al: Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology 60: 1674-1685, 2014.